image: The white areas in this image show extensive regeneration of nerve fibers (axons) in the central nervous system achieved by gene therapy after optic nerve injury. (The blue areas indicate scar tissue.) By adding a potassium channel blocking drug to this treatment, He, Fagiolini and colleagues were able to boost conduction in the regenerated nerves and thereby restore visual function. view more
Credit: Fengfeng Bei, PhD
Boston, Mass. -- Research from Boston Children's Hospital suggests the possibility of restoring at least some visual function in people blinded by optic nerve damage from glaucoma, estimated to affect more than 4 million Americans, or from trauma.
As reported online January 14 by the journal Cell, the scientists restored vision in mice with optic nerve injury by using gene therapy to get the nerves to regenerate and -- the crucial step -- adding a channel-blocking drug to help the nerves conduct impulses from the eye to the brain. In the future, they believe, the same effect could be achieved with drugs alone.
In the study, previously blind mice turned their heads to follow patterns of moving bars after given the treatment, say co-senior investigators Zhigang He, PhD, and Michela Fagiolini, PhD, of the Department of Neurology and F.M. Kirby Neurobiology Center at Boston Children's. The technicians doing the tests did not know which mice had been treated.
"By making the bars thinner and thinner, we found that the animals could not only see, but they improved significantly in how well they could see," says Fagiolini.
While other teams, including one at Boston Children's, have restored partial vision in mice, they relied on genetic techniques that can only be done in a lab. Generally, their methods involved deleting or blocking tumor suppressor genes, which encourages regeneration but could also promote cancer. The new study is the first to restore vision with an approach that could realistically be used in the clinic, and that does not interfere with tumor suppressor genes.
Getting nerves to conduct
The key advance in restoring vision was getting the regenerated nerve fibers (axons) to not only form working connections with brain cells, but also to carry impulses (action potentials) all the way from the eye to the brain. The challenge was that the fibers regrow without the insulating sheath known as myelin, which helps propagate nerve signals over long distances.
"We found that the regenerated axons are not myelinated and have very poor conduction -- the travel speed is not high enough to support vision," says He. "We needed some way to overcome this issue."
Turning to the medical literature, they learned that a potassium channel blocker, 4-aminopyridine (4-AP), helps strengthen nerve signals when myelin is absent. The drug is marketed as AMPYRA for multiple sclerosis, which also involves a loss of myelin. When they added it, the signals were able to go the distance.
A paradigm for treating glaucoma and optic nerve injury
While the study used a gene therapy virus called AAV to deliver the growth factors that trigger regeneration (osteopontin, insulin-like growth factor 1 and ciliary neurotrophic factor), He and Fagiolini are testing whether injecting a "cocktail" of growth factor proteins directly into the eye could be equally effective.
"We're trying to better understand the mechanisms and how often the proteins would have to be injected," says He. "The gene therapy virus we used is approved for clinical study in eye disease, but a medication would be even better."
With regeneration kick-started, 4-AP or a similar drug could then be given systemically to maintain nerve conduction. Because 4-AP has potential side effects including seizures if given chronically, He and Fagiolini have begun testing derivatives (not yet FDA-approved) that are potentially safer for long-term use.
The researchers are further testing the mice to better understand the extent of visual recovery and whether their approach might get myelin to regrow over time.
"The drugs might need to be paired with visual training to facilitate recovery," says Fagiolini. "But now we have a paradigm to push forward."
###
Fengfeng Bei, PhD, and Hing Cheong (Henry) Lee, MPhil, of the F.M. Kirby Neurobiology Center at Boston Children's, were co-first authors on the paper. The study was supported by the National Eye Institute, the Miriam and Sheldon G. Adelson Medical Research Foundation and the Croucher Foundation.
About Boston Children's Hospital:
Boston Children's Hospital is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited children and adults since 1869. More than 1,100 scientists, including seven National Academy of Sciences members, 11 Institute of Medicine members and 10 Howard Hughes Medical Institute members comprise Boston Children's research community. Founded as a 20-bed hospital, Boston Children's today is a 404-bed comprehensive center for pediatric and adolescent health care and the primary pediatric teaching affiliate of Harvard Medical School. For more, visit our Vector and Thriving blogs and follow us on @BostonChildrens, @BCH_Innovation, Facebook and YouTube.
Journal
Cell